BiotechTube

vigabatrin + placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cocaine Dependence

Conditions

Cocaine Dependence

Trial Timeline

Jan 1, 2008 → Oct 1, 2012

NCT ID
NCT00611130

About vigabatrin + placebo

vigabatrin + placebo is a phase 2 stage product being developed by Catalyst Pharmaceuticals for Cocaine Dependence. The current trial status is completed. This product is registered under clinical trial identifier NCT00611130. Target conditions include Cocaine Dependence.

What happened to similar drugs?

1 of 2 similar drugs in Cocaine Dependence were approved

Approved (1) Terminated (0) Active (1)
🔄Topiramate + Cognitive Behavioral Therapy + Placebo + Cognitive Behavioral TherapyJohnson & JohnsonPhase 3
✅quetiapineAstraZenecaApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00611130Phase 2Completed
NCT00527683Phase 2Completed

Competing Products

13 competing products in Cocaine Dependence

See all competitors
ProductCompanyStageHype Score
Topiramate + Cognitive Behavioral Therapy + Placebo + Cognitive Behavioral TherapyJohnson & JohnsonPhase 3
36
TopiramateJohnson & JohnsonPhase 2
35
quetiapineAstraZenecaApproved
43
quetiapine fumarate + Matched PlaceboAstraZenecaPre-clinical
26
AFQ056 + PlaceboNovartisPhase 1
21
AFQ056 + PlaceboNovartisPhase 2
35
ALKS 33-BUP + ALKS 33 + PlaceboAlkermesPhase 1
26
VIVITROL (Naltrexone extended-release injectable suspension) + PlaceboAlkermesPhase 2
32
Vigabatrin + Matching PlaceboCatalyst PharmaceuticalsPhase 2/3
32
Vigabatrin + PlaceboCatalyst PharmaceuticalsPhase 2
29
CPP-115 + PlaceboCatalyst PharmaceuticalsPhase 1
23
TNX-1300Tonix PharmaceuticalsPhase 2
17
TNX-1300 (Injection) + Placebo (Injection)Tonix PharmaceuticalsPhase 2
17